Targeting the PD-1/PD-L1 axis in non –small cell lung cancer

The last decade has witnessed rapid advances in the discovery and development of immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in non –small cell lung cancer (NSCLC). The proven antitumor efficacy coupled with low rates of drug-related toxicities observed, albeit idiosyncratic, with these novel immunotherapeutics have led to the registration of multiple PD-1 and PD-L1 inhibitors, such as nivolumab, pembrolizumab, and atezolizuma b, in second-line advanced NSCLC, whereas durvalumab and avelumab are in late-phase clinical testing.

Source: Current Problems in Cancer - December 22, 2016 Category: Cancer & Oncology Authors: Rajiv Kumar, Dearbhaile Collins, Saoirse Dolly, Fiona McDonald, Mary E.R. O ’Brien, Timothy A. Yap Source Type: research